Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

(2016) P. Lito et al.   SCIENCE

KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer

(2015) Peter Camaj et al.   Future Oncology

Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)

(2015) A. Stahler et al.   INTERNATIONAL JOURNAL OF CANCER

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer

(2015) Ryan B. Corcoran et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer

(2015) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

(2015) Lieke H J Simkens et al.   LANCET

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

(2015) Chiara Cremolini et al.   LANCET ONCOLOGY

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial

(2015) Susanna Hegewisch-Becker et al.   LANCET ONCOLOGY

Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features

(2014) E. Missiaglia et al.   ANNALS OF ONCOLOGY

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

(2014) Volker Heinemann et al.   LANCET ONCOLOGY

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group

(2013) W. Schmiegel et al.   ANNALS OF ONCOLOGY

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

(2013) Jonathan M. Ostrem et al.   NATURE

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306

(2012) S. Stintzing et al.   ANNALS OF ONCOLOGY

Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group

(2012) Anke Reinacher-Schick et al.   BMC CANCER

Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab

(2012) Sabine Tejpar et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

(2012) Marc Peeters et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of the Specific Mutation inKRASCodon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials

(2012) Dominik P. Modest et al.   ONCOLOGY

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

(2011) C. Bokemeyer et al.   ANNALS OF ONCOLOGY

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

(2011) T Yokota et al.   BRITISH JOURNAL OF CANCER

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer

(2010) Ludwig Fischer von Weikersthal et al.   EUROPEAN JOURNAL OF CANCER

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

(2010) Wendy De Roock et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer

(2009) Jens Neumann et al.   PATHOLOGY RESEARCH AND PRACTICE